Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Proposes Extra Payments On CustomFlex Iris, Single-Use Duodenoscope, Heart Device

Medicare agency discusses unique nature of devices in outpatient payment system proposed rule

Executive Summary

The Centers for Medicare and Medicaid Services highlighted three FDA breakthrough devices it is proposing for additional pass-through payments in its 2021 outpatient pay rule.

You may also be interested in...



VEO Ophthalmics’ Artificial Iris, Boston Scientific’s Single-Use Duodenoscope Win Pass-Through Payments

US CMS described several products winning device pass-through payment status for 2021 in an outpatient prospective payment system final rule.

Azalea Vision Formed To Develop Artificial Iris

Researchers have created the "smart contact lens" to dynamically improve the vision of people with various optical defects.

‘Right Product, Right Time:’ FDA Clears Boston Scientific's Single-Use Duodenoscope

Amid concerns of infections from duodenoscopes that are not sufficiently re-sterilized, the US FDA has cleared Boston Scientific’s Exalt-D as a the first single-use duodenoscope. Investors expect the device will likely take a significant chunk of the market, especially considering the next competitor is at least a year away.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT142570

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel